ScholarIQanswers from OpenAlex & ORCID
Daniel P. Petrylak
ResearcherPublications, citations & collaboration network
Daniel P. Petrylak is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Daniel P. Petrylak have?
ScholarIQindexed works
Daniel P. Petrylak has 830 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Daniel P. Petrylak have?
ScholarIQcitation count
Daniel P. Petrylak has 46,455 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Daniel P. Petrylak?
ScholarIQh-index
Daniel P. Petrylak has an h-index of 88 in OpenAlex.
What is the i10-index of Daniel P. Petrylak?
ScholarIQi10-index
Daniel P. Petrylak has an i10-index of 344 in OpenAlex.
What is the ORCID of Daniel P. Petrylak?
ScholarIQorcid
The ORCID for Daniel P. Petrylak is on the source record.
What is the OpenAlex record for Daniel P. Petrylak?
ScholarIQopenalex
The OpenAlex for Daniel P. Petrylak is on the source record.
What are the most-cited papers on Daniel P. Petrylak?
ScholarIQmost cited works
Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial
Jonathan E. Rosenberg, Jean Hoffman‐Censits, Tom Powles, Michiel S. van der Heijden, Arjun Vasant Balar, Andrea Necchi, Nancy A. Dawson, Peter H. O’Donnell, Ani Sarkis Balmanoukian, Yohann Loriot, Sandy Srinivas, Margitta Retz, Petros Grivas, Richard W. Joseph, Matthew D. Galsky, Mark T. Fleming, Daniel P. Petrylak, José Luis Perez‐Gracia, Howard A. Burris, Daniel Castellano, Christina Canil, Joaquim Bellmunt, Dean F. Bajorin, Dorothee Nickles, Richard Bourgon, Garrett M. Frampton, Na Cui, Sanjeev Mariathasan, Oyewale O. Abidoye, Gregg Fine, Robert Dreicer
Docetaxel and Estramustine Compared with Mitoxantrone and Prednisone for Advanced Refractory Prostate Cancer
Daniel P. Petrylak, Catherine M. Tangen, Maha Hussain, Primo N. Lara, Jeffrey A. Jones, Mary Ellen Taplin, Patrick A. Burch, Donna L. Berry, Carol M. Moinpour, Manish Kohli, Mitchell C. Benson, Eric J. Small, Derek Raghavan, E. David Crawford
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
Joaquim Bellmunt, Ronald de Wit, David J. Vaughn, Yves Fradet, Jae‐Lyun Lee, Lawrence Fong, Nicholas J. Vogelzang, Miguel Ángel Climent, Daniel P. Petrylak, Toni K. Choueiri, Andrea Necchi, Winald R. Gerritsen, Howard Gurney, David I. Quinn, Stéphane Culine, Cora N. Sternberg, Yabing Mai, Christian Poehlein, Rodolfo F. Perini, Dean F. Bajorin
Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma
Thomas Powles, Se Hoon Park, Éric Voog, Claudia Caserta, Begoña P. Valderrama, Howard Gurney, Haralabos P. Kalofonos, Siniša Radulović, Wim Demey, Anders Ullén, Yohann Loriot, Srikala S. Sridhar, Norihiko Tsuchiya, Evgeny Kopyltsov, Cora N. Sternberg, Joaquim Bellmunt, Jeanny B. Aragon‐Ching, Daniel P. Petrylak, Robert J Laliberte, Jing Wang, Bo Huang, Craig B. Davis, Camilla Fowst, Nuno Costa, John A. Blake-Haskins, Alessandra di Pietro, Petros Grivas
Eligibility and Response Guidelines for Phase II Clinical Trials in Androgen-Independent Prostate Cancer: Recommendations From the Prostate-Specific Antigen Working Group
Glenn J. Bubley, Michael A. Carducci, William L. Dahut, Nancy A. Dawson, Danai Daliani, Mario A. Eisenberger, William D. Figg, Boris Freidlin, Susan Halabi, Gary R. Hudes, Maha Hussain, Richard Kaplan, Charles E. Myers, William Oh, Daniel P. Petrylak, Eddie Reed, Bruce J. Roth, Oliver Sartor, Howard I. Scher, Jonathan W. Simons, Vickie Sinibaldi, Eric J. Small, Matthew R. Smith, Donald L. Trump, Robin T. Vollmer, George Wilding